Skip to main content
SpringerLink
Log in

Bevacizumab-Therapie im „Off-label use“ bei der neovaskulären altersabhängigen Makuladegeneration

  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3): 363–372

    Article  PubMed  Google Scholar 

  2. Folkman J (1971) Tumor Angiogenesis: Therapeutic implications. New Eng J Med 285: 1185–1186

    Google Scholar 

  3. Gonzales CR (2005) VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25(7): 815–827

    Article  PubMed  Google Scholar 

  4. Gragoudas ES, Adamis AP, Cunningham ET et al. (2004) VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27): 2805–2816

    Article  PubMed  Google Scholar 

  5. Ishida S, Usui T, Yamashiro K et al. (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198(3): 483–489

    Article  PubMed  Google Scholar 

  6. Junius P, Kuhnt H (1926) Die scheibenförmige Entartung der Netzhautmitte. Degeneratio maculae lutae disciformis. Karger, Berlin

  7. Lee JH, Canny MD, De Erkenez A et al. (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102(52): 18902–18907

    Article  PubMed  Google Scholar 

  8. Peters S, Julien S, Heiduschka P et al. (2006) Bevacizumab significantly reduces VEGF-induced permeability of choroidal endothelial cells. Exper Eye Res (submitted)

  9. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36(4): 331–335

    PubMed  Google Scholar 

  10. Senger DR, Connolly DT, Van de WL et al. (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50(6): 1774–1778

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: K. U. B.-S. ist als Mitglied des Advisory Boards und als honorierter Referent für die Firmen Pfizer und Novartis tätig. F. G. H. ist als Mitglied des Advisory Boards und als Berater für die Firmen Pfizer, Novartis, Allergan und Acucela tätig.

Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Authors and Affiliations

  1. Augenklinik, Eberhard-Karls-Universität, Schleichstraße 12, 72076 , Tübingen

    K. U. Bartz-Schmidt

  2. Augenklinik, Universität, Bonn

    F. G. Holz

Authors
  1. K. U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. G. Holz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. U. Bartz-Schmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartz-Schmidt, K.U., Holz, F.G. Bevacizumab-Therapie im „Off-label use“ bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103, 461–462 (2006). https://doi.org/10.1007/s00347-006-1351-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-006-1351-6

Search

Navigation